Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 2
1999 4
2000 7
2001 8
2002 9
2003 18
2004 27
2005 42
2006 51
2007 102
2008 109
2009 155
2010 175
2011 175
2012 203
2013 224
2014 232
2015 232
2016 241
2017 214
2018 202
2019 167
2020 151
2021 26
Text availability
Article attribute
Article type
Publication date

Search Results

2,452 results
Results by year
Filters applied: . Clear all
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
We compared the efficacy of mogamulizumab, a novel monoclonal antibody directed against C-C chemokine receptor 4, with vorinostat in patients with previously treated cutaneous T-cell lymphoma. ...Mogamulizumab therapy resulted in superior investigator-assessed progression- …
We compared the efficacy of mogamulizumab, a novel monoclonal antibody directed against C-C chemokine receptor 4, with vorinostat in …
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells.
Okubo K, Isono M, Miyai K, Asano T, Sato A. Okubo K, et al. Cancer Sci. 2020 Jan;111(1):112-126. doi: 10.1111/cas.14225. Epub 2019 Nov 25. Cancer Sci. 2020. PMID: 31675763 Free PMC article.
The HMG-CoA reductase inhibitor fluvastatin reportedly activates the mTOR inhibitor AMP-activated protein kinase (AMPK), and we thought that it would potentiate vorinostat's anticancer activity in renal cancer cells. The combination of vorinostat and fluvastatin ind …
The HMG-CoA reductase inhibitor fluvastatin reportedly activates the mTOR inhibitor AMP-activated protein kinase (AMPK), and we thought that …
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Rodriguez CP, Wu QV, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, Lee SM, Santana-Davila R, Goulart B, Baik CS, Chow LQM, Eaton K, Martins R. Rodriguez CP, et al. Clin Cancer Res. 2020 Feb 15;26(4):837-845. doi: 10.1158/1078-0432.CCR-19-2214. Epub 2019 Dec 3. Clin Cancer Res. 2020. PMID: 31796519 Clinical Trial.
PURPOSE: This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic squamous cell carcinomas of the head and neck (HN), and salivary gland cancer (SGC). ...Pembrolizumab 200 mg was given intravenous every 21 days, and vorinostat 400 mg given o …
PURPOSE: This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic squamous cell carcinomas of the head and n …
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.
Gray JE, Saltos A, Tanvetyanon T, Haura EB, Creelan B, Antonia SJ, Shafique M, Zheng H, Dai W, Saller JJ, Chen Z, Tchekmedyian N, Goas K, Thapa R, Boyle TA, Chen DT, Beg AA. Gray JE, et al. Clin Cancer Res. 2019 Nov 15;25(22):6623-6632. doi: 10.1158/1078-0432.CCR-19-1305. Epub 2019 Aug 13. Clin Cancer Res. 2019. PMID: 31409616 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Patients received intravenous pembrolizumab (200 mg every 3 weeks) plus oral vorinostat (200 or 400 mg/day). Primary endpoint was safety/tolerability. ...No DLTs were observed, and the recommended phase I dose was pembrolizumab 200 mg and vorinosta
PATIENTS AND METHODS: Patients received intravenous pembrolizumab (200 mg every 3 weeks) plus oral vorinostat (200 or 400 mg/day). Pr …
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S. Takeuchi S, et al. Cancer Sci. 2020 Feb;111(2):561-570. doi: 10.1111/cas.14260. Epub 2020 Jan 6. Cancer Sci. 2020. PMID: 31782583 Free PMC article. Clinical Trial.
In the present study, we determined the safety of vorinostat-gefitinib combination and evaluated pharmacodynamic biomarkers of vorinostat activity. ...Vorinostat doses were escalated based on a conventional 3 + 3 design. ...
In the present study, we determined the safety of vorinostat-gefitinib combination and evaluated pharmacodynamic biomarkers of vor
Vorinostat.
Grant S, Easley C, Kirkpatrick P. Grant S, et al. Nat Rev Drug Discov. 2007 Jan;6(1):21-2. doi: 10.1038/nrd2227. Nat Rev Drug Discov. 2007. PMID: 17269160 No abstract available.
Vorinostat in solid and hematologic malignancies.
Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S. Siegel D, et al. J Hematol Oncol. 2009 Jul 27;2:31. doi: 10.1186/1756-8722-2-31. J Hematol Oncol. 2009. PMID: 19635146 Free PMC article. Review.
This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial program. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic maligna …
This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from th …
Vorinostat is victorious in GVHD prevention.
Holtan SG, Weisdorf DJ. Holtan SG, et al. Blood. 2017 Oct 12;130(15):1690-1691. doi: 10.1182/blood-2017-08-802249. Blood. 2017. PMID: 29025718 No abstract available.
Vorinostat: a histone deacetylases (HDAC) inhibitor ameliorates traumatic brain injury by inducing iNOS/Nrf2/ARE pathway.
Xu J, Shi J, Zhang J, Zhang Y. Xu J, et al. Folia Neuropathol. 2018;56(3):179-186. doi: 10.5114/fn.2018.78697. Folia Neuropathol. 2018. PMID: 30509039 Free article.
Marmarou's weight-drop model was used to induce the TBI. Further, animals were treated with vorinostat 100 mg/kg intraperitoneally 30 min before the TBI induction. ...Moreover, the altered level of oxidative stress parameters, translocation of nuclear factor erythroid 2-re …
Marmarou's weight-drop model was used to induce the TBI. Further, animals were treated with vorinostat 100 mg/kg intraperitoneally 30 …
Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms.
Cardoso BA, Ramos TL, Belo H, Vilas-Boas F, Real C, Almeida AM. Cardoso BA, et al. Exp Hematol. 2019 Apr;72:60-71.e11. doi: 10.1016/j.exphem.2019.02.002. Epub 2019 Feb 13. Exp Hematol. 2019. PMID: 30769020
These can be pharmacologically manipulated with histone deacetylase inhibitors (HDACIs), which have proven to be clinically effective in the treatment of MPNs but exhibit dose-limiting toxicity. The treatment of primary MPN cells with vorinostat modulates the expression of …
These can be pharmacologically manipulated with histone deacetylase inhibitors (HDACIs), which have proven to be clinically effective in the …
2,452 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page